Breaking News Instant updates and real-time market news.

TEVA

Teva

$42.96

-1.32 (-2.98%)

, REGN

Regeneron

$371.68

-4.11 (-1.09%)

07:00
10/17/16
10/17
07:00
10/17/16
07:00

Teva, Regeneron say FDA places Phase 2b fasinumab study on clinical hold

TEVA

Teva

$42.96

-1.32 (-2.98%)

REGN

Regeneron

$371.68

-4.11 (-1.09%)

  • 30

    Oct

  • 04

    Nov

  • 06

    Nov

  • 15

    Nov

  • 29

    Mar

TEVA Teva
$42.96

-1.32 (-2.98%)

10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.
10/12/16
LEER
10/12/16
NO CHANGE
Target $70
LEER
Outperform
Neurocrine recent selloff a buying opportunity, says Leerink
Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.
REGN Regeneron
$371.68

-4.11 (-1.09%)

09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
10/13/16
BTIG
10/13/16
NO CHANGE
Target $18
BTIG
Buy
Ocular deal with Regeneron has favorable terms, says BTIG
BTIG analyst Ling Wang believes Ocular Therapeutix's (OCUL) strategic collaboration with Regeneron (REGN) comes with favorable deal terms. The back-end loaded structure brings the potential for large upside, Wang tells investors in a research note. In addition, the partnership provides external validation for Ocular's platform technology, Wang adds. The analyst reiterates a Buy rating on the shares with an $18 price target

TODAY'S FREE FLY STORIES

QVCA

QVC Group

$24.61

0.1 (0.41%)

, QVCB

QVC Group

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
FBN Securities media analyst to hold a luncheon meeting »

Media Analyst Routh…

QVCA

QVC Group

$24.61

0.1 (0.41%)

QVCB

QVC Group

LVNTA

Liberty Ventures

$52.69

1.21 (2.35%)

GNCMA

General Communications

$36.81

0.97 (2.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 10

    Jul

ICON

Iconix Brand

$6.88

-0.01 (-0.15%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Iconix Brand management to meet with Roth Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

CIR

CIRCOR

$58.61

0.95 (1.65%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
CIRCOR management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

CUTR

Cutera

$26.55

1 (3.91%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Cutera management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 30

    Jun

  • 28

    Sep

EVLV

EVINE Live

$1.02

-0.02 (-1.92%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
EVINE Live management to meet with Craig-Hallum »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

FARM

Farmer Bros.

$31.15

1.05 (3.49%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Farmer Bros. management to meet with B. Riley »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

AGNC

AGNC Investment

$21.54

-0.16 (-0.74%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
AGNC Investment management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

04:55
06/29/17
06/29
04:55
06/29/17
04:55
General news
Jobless Claims to be reported at 08:30 »

Week of 6/24 Jobless…

04:55
06/29/17
06/29
04:55
06/29/17
04:55
General news
Breaking General news story  »

Week of 6/25 Bloomberg…

04:55
06/29/17
06/29
04:55
06/29/17
04:55
General news
Breaking General news story  »

4-Week Bill Announcement…

NBIX

Neurocrine

$46.77

1.21 (2.66%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Neurocrine management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 29

    Jun

CBRL

Cracker Barrel

$167.46

0.74 (0.44%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Cracker Barrel management to meet with Maxim »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

CRNCY

Cairn Energy

$4.56

0.0998 (2.24%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Cairn Energy management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 30

    Jun

BAYRY

Bayer

$138.99

1.4 (1.02%)

, FMS

Fresenius Medical

$49.19

0.39 (0.80%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
UBS to hold a bus tour »

European Healthcare Bus…

BAYRY

Bayer

$138.99

1.4 (1.02%)

FMS

Fresenius Medical

$49.19

0.39 (0.80%)

RHHBY

Roche

$32.79

0.21 (0.64%)

NVS

Novartis

$85.25

-0.06 (-0.07%)

BPMUF

Basilea Pharmaceutica AG

$84.80

0.45 (0.53%)

GNMSF

Genmab

AZN

AstraZeneca

$34.35

-0.22 (-0.64%)

SHPG

Shire

$171.81

-0.1 (-0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 06

    Jul

  • 12

    Jul

  • 13

    Jul

  • 30

    Jul

CSV

Carriage Services

$26.85

0.06 (0.22%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Carriage Services management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 28

    Sep

WM

Waste Management

$73.52

0.41 (0.56%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Waste Management management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

FTV

Fortive

$64.41

1.04 (1.64%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Fortive has a conference call hosted by JPMorgan »

JPMorgan Analyst Tusa…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

RGA

Reinsurance Group

$128.86

2 (1.58%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Reinsurance Group management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

SRCL

Stericycle

$77.72

0.48 (0.62%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Stericycle management to meet with Barrington »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 03

    Aug

RVLT

Revolution Lighting

$6.32

-0.05 (-0.78%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Revolution Lighting management to meet with Roth Capital »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

04:55
06/29/17
06/29
04:55
06/29/17
04:55
General news
Real GDP to be reported at 08:30 »

Real GDP will be reported…

04:55
06/29/17
06/29
04:55
06/29/17
04:55
General news
Breaking General news story  »

Week of 6/28 Fed Balance…

04:55
06/29/17
06/29
04:55
06/29/17
04:55
General news
Breaking General news story  »

6-Month Bill Announcement…

BIIB

Biogen

$274.64

3.39 (1.25%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Biogen management to meet with Evercore ISI »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

  • 25

    Jul

OXM

Oxford Industries

$62.76

0.92 (1.49%)

04:55
06/29/17
06/29
04:55
06/29/17
04:55
Conference/Events
Oxford Industries management to meet with Sidoti »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.